Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

The company said sales of Mounjaro and Zepbound were hurt in the latest quarter by wholesalers cutting inventory, after they increased inventory at the end of the previous quarter. Tomi Kilgore is ...

A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Eli Lilly And Co LLY experienced a 1.37% increase in pre-market trading on Wednesday, as per Benzinga Pro. This uptick occurs ...

Lilly’s stock has risen 53.6% so far this year compared with an increase of 17.1% for the Large Cap Pharmaceuticals industry. Mounjaro was launched in mid-2022, while Zepbound was launched in ...

Tirzepatide, available as Mounjaro, has been hailed as the 'King Kong' of slimming jabs and a breakthrough in the war on obesity — more effective for shifting the pounds than similar drugs like ...

Mounjaro and Zepbound faced challenges as ... Should investors consider buying Lilly stock on the dip? I think so. The bull case for Lilly remains intact despite the company's disappointing ...

Lilly’s most popular products are its tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. However, sales of these drugs disappointed due to inventory issues ...

But those wholesalers tapped into some of that existing stock in the third quarter instead of buying more from the company, which dampened revenue from both treatments, Eli Lilly said. Mounjaro ...

Paul Joyce receives funding from The Hospital Research Foundation, Cancer Council SA, and the Australian Research Council. He is Director of the Australian Controlled Release Society. Srinivas ...